Filing Flows › Ionis Pharmaceuticals (IONS) › Q1 2026 › vs Q4 2025
Ionis Pharmaceuticals (IONS) Q1 2026 vs Q4 2025 (quarter over quarter)
Ionis Pharmaceuticals's revenue rose $42.8M (+21%) from $203M in Q4 2025 to $246M in Q1 2026.
Ionis Pharmaceuticals, Q1 2026: revenue $246M (+87% year over year), operating margin -47.7%, net loss $92.5M, operating cash flow −$793M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $246M | $203M | $42.8M | +21% |
| Other income, net | $25.1M | −$13.5M | $38.6M | — |
| Net loss | $92.5M | $229M | −$137M | -60% |
| Costs & expenses | $364M | $433M | −$69.0M | -16% |
| Operating costs | $364M | $418M | −$54.3M | -13% |
| Income tax | $218K | $1.5M | −$1.3M | -85% |
| Cost of revenue | $3.0M | $8.0M | −$5.0M | -63% |
| SG&A | $150M | $130M | $20.2M | +15% |
| Other operating costs | $210M | $280M | −$69.5M | -25% |
| Operating cash sources | $840M | $185M | $655M | +354% |
| Depreciation & amortization | $4.0M | $3.9M | $65K | +2% |
| Share-based compensation | $43.3M | $43.3M | −$45K | -0.1% |
| Cash used in operations | $793M | $138M | $655M | +476% |
| Net loss absorbed | $92.5M | $229M | −$137M | -60% |
| Working capital & other | $748M | −$44.5M | $792M | — |
Questions
How much did Ionis Pharmaceuticals's revenue grow quarter over quarter in Q1 2026?
Ionis Pharmaceuticals's revenue rose $42.8M (+21%) from $203M in Q4 2025 to $246M in Q1 2026.